Welcome to our dedicated page for First Tracks Biotherapeutics SEC filings (Ticker: TRAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on First Tracks Biotherapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into First Tracks Biotherapeutics's regulatory disclosures and financial reporting.
First Tracks Biotherapeutics director John P. Schmid received new equity awards as part of his compensation. He was granted stock options covering 42,000 shares of common stock at an exercise price of $17.81 per share, expiring on 2036-05-11.
The option vests in equal monthly installments, with 1/12 of the shares vesting each month starting on 2026-06-12, as long as he continues serving the company. Schmid also received 15,000 restricted stock units, each representing a right to one share of common stock at no cost upon settlement.
These RSUs vest 100% on the date of First Tracks Biotherapeutics’ 2027 annual shareholder meeting, subject to continued service. In addition to the newly granted 42,000 options, he already holds options to purchase up to an aggregate of 107,320 shares of common stock that vest according to their existing terms.
First Tracks Biotherapeutics director Rita Jain received new equity awards in the form of options and restricted stock units. She was granted options to buy 42,000 shares of common stock at an exercise price of $17.81 per share, expiring on May 11, 2036.
She also received 15,000 restricted stock units, each representing one share of common stock upon settlement for no cash consideration. The RSUs vest 100% on the date of the company’s 2027 annual shareholder meeting, while the options vest in 12 equal monthly installments starting June 12, 2026 as long as she continues serving the company.
First Tracks Biotherapeutics director John A. Orwin received new equity awards. He was granted options to buy 42,000 shares of common stock at an exercise price of $17.81 per share, vesting in 12 equal monthly installments starting on June 12, 2026, as long as he continues serving the company.
Orwin also received 15,000 restricted stock units, each representing one share of common stock for no cash cost upon settlement. These RSUs vest 100% on the date of the company’s 2027 annual shareholder meeting, subject to continued service. A footnote notes he also holds other options covering up to 55,181 shares that vest under their existing terms.
First Tracks Biotherapeutics director Dennis M. Fenton received new equity awards as part of his compensation. He was granted options to buy 42,000 shares of common stock at an exercise price of $17.81 per share, expiring on May 11, 2036. These options vest in equal monthly installments over 12 months beginning June 12, 2026, so he earns them gradually by continuing to serve the company.
He was also granted 15,000 restricted stock units, each representing one share of common stock for no cash payment. These RSUs vest in full on the date of the company’s 2027 annual shareholder meeting, if he is still providing service. In addition to the 42,000 new options, he holds other options to purchase up to 97,827 shares that vest under their existing terms.
First Tracks Biotherapeutics granted Chief Business Officer Benjamin Stone new equity awards tied to the company’s common stock. He received an option to buy 72,300 shares at an exercise price of $17.81 per share, expiring on May 11, 2036. The option vests 25% on May 12, 2027, then in equal monthly installments over four years, conditioned on continued service.
Stone was also awarded 26,700 restricted stock units, each representing one share of common stock upon settlement for no consideration. These RSUs vest 25% annually starting on May 12, 2027, also subject to ongoing service. In addition to the new grant, he already holds options to purchase up to 337,140 shares of common stock under existing award terms.
First Tracks Biotherapeutics, Inc. reported that President and CEO Daniel Faga received new equity awards as part of his compensation. He was granted options to purchase 271,100 shares of common stock at an exercise price of $17.81 per share, expiring on May 11, 2036.
These stock options vest 25% on May 12, 2027, then in equal monthly installments over 48 months, contingent on continued service. Faga also received 100,200 restricted stock units, each representing one share of common stock for no cash consideration, vesting 25% annually from May 12, 2027 until fully vested, also subject to continued service. A footnote states he holds additional options to purchase up to 1,035,941 shares that vest under their own terms.
First Tracks Biotherapeutics Chief Financial Officer Ajim Tamboli received new equity awards as part of compensation. On May 12, 2026, he was granted options to purchase 13,600 shares of common stock at an exercise price of $17.81 per share, expiring on May 11, 2036.
The option vests 25% on May 12, 2027 and then in equal monthly installments over the following three years, contingent on continued service. He also received 5,000 restricted stock units, with 25% of the RSUs vesting annually starting on May 12, 2027, also subject to continued service.
In addition to this new grant of 13,600 options, he holds other options covering up to 123,700 shares of common stock that vest according to their existing terms. These awards are non-cash grants and do not represent open-market share purchases or sales.
First Tracks Biotherapeutics Chief Medical Officer Paul F. Lizzul received new equity awards. He was granted employee stock options for 72,300 shares of common stock at an exercise price of $17.81 per share, expiring on May 11, 2036. These options vest 25% on May 12, 2027, then 1/48 of the total shares monthly until fully vested, contingent on continued service.
He also received 26,700 restricted stock units, each representing a right to receive one share of common stock for no cash payment. The RSUs vest 25% annually starting on May 12, 2027, subject to ongoing service. There were no open-market purchases or sales reported. A footnote states he also holds separate options to purchase up to 507,310 shares of common stock that vest under their own terms.
First Tracks Biotherapeutics, Inc. is registering 10,497,054 shares of common stock for resale by existing stockholders under a Form S-1 registration statement. The company will not receive any proceeds from these resale transactions.
First Tracks was spun off from AnaptysBio, Inc. on April 20, 2026 and now trades on Nasdaq under the symbol TRAX, with a May 7, 2026 closing price of $17.82 per share. In a March 2026 private placement tied to the spin-off, First Tracks sold 5,791,479 primary shares and investors purchased 4,705,575 secondary shares at $13.81 per share, generating approximately $80 million in gross proceeds for the company.
First Tracks is a clinical-stage biotechnology company developing immunology therapeutics for autoimmune and inflammatory diseases, led by antibodies rosnilimab, ANB033 and ANB101. The business reported a 2025 net loss of $166.1 million and had $238.2 million in cash and cash equivalents as of December 31, 2025, and expects its existing cash, cash equivalents and investments to fund its current operating plan beyond the next 12 months. The company qualifies as an emerging growth company and a smaller reporting company, allowing reduced disclosure and compliance obligations.